Cationic Nanoparticles Enhance Viral Infectious Capacity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Modified viruses used in virotherapy have a restricted infectious capacity, requiring large quantities for therapeutic effects, and existing methods to enhance their potency are limited by factors like serum inhibition and the need for magnetic fields.

Innovation Solution

Combining cationic nanoparticles with live viruses, particularly non-enveloped viruses, to enhance their infectious capacity by improving endocytosis and escape from endocytic vesicles, allowing for lower viral concentrations to achieve therapeutic effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If modified viruses are used for virotherapy, then therapeutic applications can be achieved, but infectious capacity is restricted requiring large quantities

Engineering Contradiction:
Improvetherapeutic effectVSAvoidviral load
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the surface charge parameter of the virus by coating with cationic nanoparticles, transforming the viral surface properties to enhance cellular interaction and endocytosis, thereby increasing infectious capacity without changing the viral genetic material

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite structure by coating viruses with cationic nanoparticles, combining the biological functionality of the virus with the surface properties of the nanoparticles to achieve enhanced cellular uptake and infectious capacity

Inventive Principle:
Principle #40Composite materials

2Reliability

If magnetic nanoparticles are used to enhance viral potency, then oncolytic effectiveness is improved, but application is limited by requirement of magnetic field

Engineering Contradiction:
Improveoncolytic potencyVSAvoidapplication flexibility
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts the magnetic field dependency from the system by replacing magnetic nanoparticles with cationic nanoparticles, retaining the viral enhancement function while eliminating the constraint of requiring external magnetic field application

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses cationic nanoparticles as an intermediary between the virus and the cell surface, mediating enhanced cellular uptake through electrostatic interactions without requiring external field application like magnetic nanoparticles

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of cationic nanoparticles with live viruses increases their infectious capacity by 10- to 1000-fold, improving viral production yields and stability, enabling effective therapeutic applications with reduced viral loads.

Implementation Method 1

The present inventors believe that nanoparticles enhance the infectious capacity of viruses by improving their endocytosis and/or by improving their capacity to escape from endocytic vesicles.

Methodology Applied
Scientific EffectEndocytosis:

Implementation Method 2

The present inventors believe that nanoparticles enhance the infectious capacity of viruses by improving their endocytosis and/or by improving their capacity to escape from endocytic vesicles.

Methodology Applied
Scientific EffectMembrane interaction:

Data Source

PatentEP3551174A1Cationic nanoparticles for enhancing infectious capacity of live viruses
Publication Date: 2019.10.16 CENT HOSPITALER & UNIV DE LILLE

AI summary

The present invention relates to a combination of cationic nanoparticles and viruses and uses thereof. The invention particularly relates to the use of nanoparticles for enhancing the infectious capacity of a live virus, preferably a non-enveloped live virus.